GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzymatica AB (FRA:EN9) » Definitions » Cash-to-Debt

Enzymatica AB (FRA:EN9) Cash-to-Debt : 79.77 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Enzymatica AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Enzymatica AB's cash to debt ratio for the quarter that ended in Sep. 2024 was 79.77.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Enzymatica AB could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Enzymatica AB's Cash-to-Debt or its related term are showing as below:

FRA:EN9' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17   Med: 2.33   Max: No Debt
Current: 79.82

During the past 13 years, Enzymatica AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.17. And the median was 2.33.

FRA:EN9's Cash-to-Debt is ranked better than
87.67% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 0.935 vs FRA:EN9: 79.82

Enzymatica AB Cash-to-Debt Historical Data

The historical data trend for Enzymatica AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Enzymatica AB Cash-to-Debt Chart

Enzymatica AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.26 1.66 12.17 2.27 0.46

Enzymatica AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.46 0.96 0.30 79.77

Competitive Comparison of Enzymatica AB's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's Cash-to-Debt falls into.



Enzymatica AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Enzymatica AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Enzymatica AB's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymatica AB  (FRA:EN9) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Enzymatica AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Enzymatica AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymatica AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

Enzymatica AB Headlines

No Headlines